newsfilter
← Earnings
Earnings Releases·

IDEXX Laboratories — Third Quarter 2026 Earnings Summary

  • Third quarter 2026 revenue reached $1,214 million (up 10% YoY), while EPS rose 18% to $4.01, driven by 12% gross profit growth and margin expansion to 62.9%.
  • Full-year 2026 guidance was raised for revenue ($4,741M–$4,767M) and EPS ($14.96–$15.16), though operating margin guidance was lowered to 32.1%–32.3%.
  • Strategic momentum continues with 10% organic growth in the Companion Animal Group, an 11% expansion in the global premium instrument installed base, and the acquisition of AI assistant CoVet.
  • Capital allocation remains aggressive with $816 million in stock repurchases during the first nine months of 2026, alongside strong free cash flow of $978 million.
Company
IDEXX LABORATORIES INC
Sector
Healthcare
Industry
Diagnostics & Research